Medical therapy for benign prostatic hyperplasia--present and future impact

Area of Science:

• Urology
• Pharmacoeconomics
• Managed Care Pharmacy

Background:

• Enlarged prostate (EP) presents significant clinical and economic challenges within managed care systems.
• Understanding the comparative effectiveness and cost-effectiveness of available pharmacologic treatments is crucial for optimal patient care and resource allocation.

Purpose of the Study:

• To provide clinicians, health plan decision-makers, and policymakers with key findings on enlarged prostate (EP) from a managed care perspective.
• To introduce and summarize three studies evaluating dutasteride and finasteride in a real-world, managed care setting.
• To aid managed care formulary decision-makers in assessing clinical and economic data to differentiate dutasteride and finasteride.

Main Methods:

• Review of existing literature on EP prevalence, economic burden, clinical characteristics, pathophysiology, and pharmacologic treatments.
• Introduction of three original research articles analyzing real-world data from a managed care population.
• Focus on comparative analysis of dutasteride and finasteride regarding acute urinary retention, surgery rates, alpha blocker discontinuation, and cost implications.

Main Results:

• The supplement introduces studies comparing dutasteride and finasteride on acute urinary retention and surgery attenuation rates.
• Differences in alpha blocker discontinuation rates when combined with dutasteride or finasteride are investigated.
• Cost implications associated with dutasteride and finasteride therapy are addressed, considering factors beyond ingredient cost.

Conclusions:

• The presented data aims to assist managed care formulary decision-makers in evaluating clinical and economic factors for dutasteride and finasteride.
• While not proving superiority, the information addresses key questions regarding the comparative value of these enlarged prostate treatments.
• The supplement highlights the importance of real-world evidence in differentiating pharmacologic options for enlarged prostate management.